Related Experiment Video

Updated: Jul 24, 2026

Efficient Derivation of Human Cardiac Precursors and Cardiomyocytes from Pluripotent Human Embryonic Stem Cells with Small Molecule Induction
10:46

Efficient Derivation of Human Cardiac Precursors and Cardiomyocytes from Pluripotent Human Embryonic Stem Cells with Small Molecule Induction

Published on: November 3, 2011

Cardiomyocyte enrichment in differentiating ES cell cultures: strategies and applications

K B Pasumarthi1, L J Field

  • 1Herman B. Wells Center for Pediatric Research, James Whitcomb Riley Hospital for Children, Indianapolis, IN, USA.

Methods in Molecular Biology (Clifton, N.J.)
|January 5, 2002
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
13:18

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

Published on: June 28, 2013

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Related Experiment Videos

Last Updated: Jul 24, 2026

Efficient Derivation of Human Cardiac Precursors and Cardiomyocytes from Pluripotent Human Embryonic Stem Cells with Small Molecule Induction
10:46

Efficient Derivation of Human Cardiac Precursors and Cardiomyocytes from Pluripotent Human Embryonic Stem Cells with Small Molecule Induction

Published on: November 3, 2011

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
13:18

Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells

Published on: June 28, 2013

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Related Concept Videos

Embryonic Stem Cells00:58

Embryonic Stem Cells

Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
Embryonic Stem Cells00:57

Embryonic Stem Cells

Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Articles linked to this work by shared authors, journal, and citation graph.

Cardiovascular research in transgenic animals.

Trends in cardiovascular medicine·2011

Expression of a transgene encoding mutant p193/CUL7 preserves cardiac function and limits infarct expansion after myocardial infarction.

Heart (British Cardiac Society)·2009

Cardiac repair by embryonic stem-derived cells.

Handbook of experimental pharmacology·2005

Scalable production of embryonic stem cell-derived cardiomyocytes.

Tissue engineering·2003

Evaluation of numerical sediment quality targets for the St. Louis River Area of Concern.

Archives of environmental contamination and toxicology·2002

Application of a sigmapolycyclic aromatic hydrocarbon model and a logistic regression model to sediment toxicity data based on a species-specific, water-only LC50 toxic unit for Hyalella azteca.

Environmental toxicology and chemistry·2001

Protocol for Detecting and Sequencing Chikungunya Virus from Field-Collected Mosquitoes.

Methods in molecular biology (Clifton, N.J.)·2026

Optimized Amplicon Strategy for Long-Read Sequencing of the Chikungunya Virus Genome.

Methods in molecular biology (Clifton, N.J.)·2026

Workflow for Long-Read Amplicon Sequencing of Chikungunya Virus Using Oxford Nanopore Technology.

Methods in molecular biology (Clifton, N.J.)·2026

Nanopore Sequencing for Chikungunya Virus: Principles and Application.

Methods in molecular biology (Clifton, N.J.)·2026

Global Genomic Surveillance.

Methods in molecular biology (Clifton, N.J.)·2026

Assessing the Vector Competence for Chikungunya Virus in Mosquitoes.

Methods in molecular biology (Clifton, N.J.)·2026

Construction and verification of a nomogram to predict the probability of venous thromboembolism in lung cancer patients.

Frontiers in molecular biosciences·2026

Research on prognostic prediction of colorectal cancer based on multi-dimensional biomarker features and machine learning models.

Frontiers in oncology·2026

A partial response to atezolizumab in alveolar soft part sarcoma with near-complete resolution of extensive pulmonary metastases: a case report.

Frontiers in oncology·2026

Metabolites from blood and formalin-fixed, paraffin-embedded tissue from participants with low- and high-grade prostate cancer: a pilot study.

Frontiers in oncology·2026

Increased HIF-2α and CD105 (endoglin) expression is associated with poor differentiation in pheochromocytomas and paragangliomas.

Frontiers in endocrinology·2026

Case Report: Neuroendocrine-low POU2F3-positive small cell lung cancer presenting as a diagnostically unstable thoracic malignancy.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us